Cisapride protects against cardiac hypertrophy via inhibiting the up-regulation of calcineurin and NFATc-3. 2014

Xin Zhou, and Qi Zhang, and Tianyang Zhao, and Xiaopeng Bai, and Wei Yuan, and Yanping Wu, and Di Liu, and Shuang Li, and Jiaming Ju, and Samuel Chege Gitau, and Wenfeng Chu, and Chaoqian Xu, and Yanjie Lu
Department of Pharmacology (Key Laboratory of Cardiovascular Medicine Research, Ministry of Education; State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin Medical University, Harbin, Heilongjiang 150081, PR China.

Cisapride has been shown to have electrophysiological effects on the heart. The aim of this study was to investigate whether cisapride has effects on cardiac hypertrophy. Rat and cellular models of cardiac hypertrophy were used in this study. Cell surface area (CSA), mRNA and protein expression were used to evaluate cardiac hypertrophy. Cardiac function was measured by echocardiography. Cisapride attenuated ISO-induced increase in CSA in a dose-dependent manner in cultured neonatal rat cardiomyocytes. A significant anti-hypertrophic effect was achieved by cisapride 0.01μM (P<0.05). Cisapride repressed the increased mRNA levels of ANP, BNP, β-MHC in ISO-treated cells (P<0.05). However, mallotoxin or GR113808 did not influence anti-hypertrophic effects of cisapride. In addition, cisapride inhibited the increase of intracellular Ca(2+) ([Ca(2+)]i) and the upregulation of protein levels of calcineurin and NFATc-3 (P<0.05) as well as prevented the downregulation of p-NFATc-3 (P<0.01) induced by ISO. Consistently, cisapride (0.5mg/kg/day) produced inhibitory effects on cardiac hypertrophy, including the suppression of ANP, BNP, β-MHC, calcineurin, and NFATc-3; elevation of p-NFATc-3; reduction of cross-sectional area of cardiomyocytes in rat heart; and restoration of cardiac dysfunction by improving left ventricular diastolic and systolic performance. Importantly, cisapride 0.5 and 5.0mg/kg/day did not cause prolongation of QT and QTc intervals in rats. In conclusion, cisapride possesses a prominent anti-hypertrophic property which is likely to be conferred by its ability to downregulate Ca(2+)/calcineurin/NFAT and the present data provide new insight into this drug action.

UI MeSH Term Description Entries
D008297 Male Males
D002316 Cardiotonic Agents Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). Cardiac Stimulant,Cardiac Stimulants,Cardioprotective Agent,Cardioprotective Agents,Cardiotonic,Cardiotonic Agent,Cardiotonic Drug,Inotropic Agents, Positive Cardiac,Myocardial Stimulant,Myocardial Stimulants,Cardiotonic Drugs,Cardiotonics,Agent, Cardioprotective,Agent, Cardiotonic,Drug, Cardiotonic,Stimulant, Cardiac,Stimulant, Myocardial
D006332 Cardiomegaly Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES. Cardiac Hypertrophy,Enlarged Heart,Heart Hypertrophy,Heart Enlargement,Cardiac Hypertrophies,Enlargement, Heart,Heart Hypertrophies,Heart, Enlarged,Hypertrophies, Cardiac,Hypertrophies, Heart,Hypertrophy, Cardiac,Hypertrophy, Heart
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015854 Up-Regulation A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Up-Regulation,Upregulation,Up-Regulation (Physiology),Up Regulation
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D050778 NFATC Transcription Factors A family of transcription factors characterized by the presence of highly conserved calcineurin- and DNA-binding domains. NFAT proteins are activated in the CYTOPLASM by the calcium-dependent phosphatase CALCINEURIN. They transduce calcium signals to the nucleus where they can interact with TRANSCRIPTION FACTOR AP-1 or NF-KAPPA B and initiate GENETIC TRANSCRIPTION of GENES involved in CELL DIFFERENTIATION and development. NFAT proteins stimulate T-CELL activation through the induction of IMMEDIATE-EARLY GENES such as INTERLEUKIN-2. NFAT Transcription Factor 1,NFAT Transcription Factor 2,NFAT Transcription Factor 3,NFAT Transcription Factor 4,NFAT Transcription Factor 5,Nuclear Factors of Activated T-Cells,NF-AT Proteins,NF-AT3 Protein,NF-AT4 Protein,NF-ATc1 Protein,NFAT Proteins,NFAT-1 Protein,NFAT-2 Protein,NFAT1 Protein,NFAT2 Protein,NFAT3 Protein,NFAT4 Protein,NFAT5 Protein,NFATC Proteins,NFATC1 Protein,NFATC1 Transcription Factor,NFATC2 Protein,NFATC2 Transcription Factor,NFATC3 Protein,NFATC3 Transcription Factor,NFATC4 Protein,NFATC4 Transcription Factor,NFATL1 Protein,NFATx Protein,NFATz Protein,Nuclear Factor of Activated T-Cells 5 Protein,Nuclear Factor of Activated T-Cells, Cytoplasmic,Nuclear Factor of Activated T-Cells, Cytoplasmic 1 Protein,Nuclear Factor of Activated T-Cells, Cytoplasmic 2 Protein,Nuclear Factor of Activated T-Cells, Cytoplasmic 3 Protein,Nuclear Factor of Activated T-Cells, Cytoplasmic 4 Protein,OREBP Protein,Osmotic Response Element Binding Protein,TonEBP Protein,Tonicity-Responsive Enhancer-Binding Protein,Transcription Factor NF-AT,Factor, NFATC1 Transcription,Factor, NFATC2 Transcription,Factor, NFATC3 Transcription,NF AT Proteins,NF AT3 Protein,NF AT4 Protein,NF ATc1 Protein,NF-AT, Transcription Factor,NFAT 1 Protein,NFAT 2 Protein,Nuclear Factor of Activated T Cells 5 Protein,Nuclear Factor of Activated T Cells, Cytoplasmic,Nuclear Factor of Activated T Cells, Cytoplasmic 1 Protein,Nuclear Factor of Activated T Cells, Cytoplasmic 2 Protein,Nuclear Factor of Activated T Cells, Cytoplasmic 3 Protein,Nuclear Factor of Activated T Cells, Cytoplasmic 4 Protein,Nuclear Factors of Activated T Cells,Tonicity Responsive Enhancer Binding Protein,Transcription Factor NF AT,Transcription Factor, NFATC1,Transcription Factor, NFATC2,Transcription Factor, NFATC3,Transcription Factor, NFATC4,Transcription Factors, NFATC
D019703 Calcineurin A CALCIUM and CALMODULIN-dependent serine/threonine protein phosphatase that is composed of the calcineurin A catalytic subunit and the calcineurin B regulatory subunit. Calcineurin has been shown to dephosphorylate a number of phosphoproteins including HISTONES; MYOSIN LIGHT CHAIN; and the regulatory subunits of CAMP-DEPENDENT PROTEIN KINASES. It is involved in the regulation of signal transduction and is the target of an important class of immunophilin-immunosuppressive drug complexes. Calcineurin A,Calcineurin B,Protein Phosphatase-2B,Protein Phosphatase 3,Protein Phosphatase 3 Catalytic Subunit,Protein Phosphatase 3 Regulatory Subunit,Phosphatase 3, Protein,Protein Phosphatase 2B
D020117 Cisapride A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed) Propulsid,R-51619,R 51619,R51619
D032383 Myocytes, Cardiac Striated muscle cells found in the heart. They are derived from cardiac myoblasts (MYOBLASTS, CARDIAC). Cardiomyocytes,Muscle Cells, Cardiac,Muscle Cells, Heart,Cardiac Muscle Cell,Cardiac Muscle Cells,Cardiac Myocyte,Cardiac Myocytes,Cardiomyocyte,Cell, Cardiac Muscle,Cell, Heart Muscle,Cells, Cardiac Muscle,Cells, Heart Muscle,Heart Muscle Cell,Heart Muscle Cells,Muscle Cell, Cardiac,Muscle Cell, Heart,Myocyte, Cardiac

Related Publications

Xin Zhou, and Qi Zhang, and Tianyang Zhao, and Xiaopeng Bai, and Wei Yuan, and Yanping Wu, and Di Liu, and Shuang Li, and Jiaming Ju, and Samuel Chege Gitau, and Wenfeng Chu, and Chaoqian Xu, and Yanjie Lu
April 2011, International journal of biological sciences,
Xin Zhou, and Qi Zhang, and Tianyang Zhao, and Xiaopeng Bai, and Wei Yuan, and Yanping Wu, and Di Liu, and Shuang Li, and Jiaming Ju, and Samuel Chege Gitau, and Wenfeng Chu, and Chaoqian Xu, and Yanjie Lu
August 2013, Naunyn-Schmiedeberg's archives of pharmacology,
Xin Zhou, and Qi Zhang, and Tianyang Zhao, and Xiaopeng Bai, and Wei Yuan, and Yanping Wu, and Di Liu, and Shuang Li, and Jiaming Ju, and Samuel Chege Gitau, and Wenfeng Chu, and Chaoqian Xu, and Yanjie Lu
October 2017, Molecular medicine reports,
Xin Zhou, and Qi Zhang, and Tianyang Zhao, and Xiaopeng Bai, and Wei Yuan, and Yanping Wu, and Di Liu, and Shuang Li, and Jiaming Ju, and Samuel Chege Gitau, and Wenfeng Chu, and Chaoqian Xu, and Yanjie Lu
January 2014, Planta medica,
Xin Zhou, and Qi Zhang, and Tianyang Zhao, and Xiaopeng Bai, and Wei Yuan, and Yanping Wu, and Di Liu, and Shuang Li, and Jiaming Ju, and Samuel Chege Gitau, and Wenfeng Chu, and Chaoqian Xu, and Yanjie Lu
September 2016, Molecular medicine reports,
Xin Zhou, and Qi Zhang, and Tianyang Zhao, and Xiaopeng Bai, and Wei Yuan, and Yanping Wu, and Di Liu, and Shuang Li, and Jiaming Ju, and Samuel Chege Gitau, and Wenfeng Chu, and Chaoqian Xu, and Yanjie Lu
January 2019, Journal of cellular and molecular medicine,
Xin Zhou, and Qi Zhang, and Tianyang Zhao, and Xiaopeng Bai, and Wei Yuan, and Yanping Wu, and Di Liu, and Shuang Li, and Jiaming Ju, and Samuel Chege Gitau, and Wenfeng Chu, and Chaoqian Xu, and Yanjie Lu
November 2017, Journal of pharmacological sciences,
Xin Zhou, and Qi Zhang, and Tianyang Zhao, and Xiaopeng Bai, and Wei Yuan, and Yanping Wu, and Di Liu, and Shuang Li, and Jiaming Ju, and Samuel Chege Gitau, and Wenfeng Chu, and Chaoqian Xu, and Yanjie Lu
January 2019, Oxidative medicine and cellular longevity,
Xin Zhou, and Qi Zhang, and Tianyang Zhao, and Xiaopeng Bai, and Wei Yuan, and Yanping Wu, and Di Liu, and Shuang Li, and Jiaming Ju, and Samuel Chege Gitau, and Wenfeng Chu, and Chaoqian Xu, and Yanjie Lu
August 2015, Journal of hypertension,
Xin Zhou, and Qi Zhang, and Tianyang Zhao, and Xiaopeng Bai, and Wei Yuan, and Yanping Wu, and Di Liu, and Shuang Li, and Jiaming Ju, and Samuel Chege Gitau, and Wenfeng Chu, and Chaoqian Xu, and Yanjie Lu
October 2004, Biochemical and biophysical research communications,
Copied contents to your clipboard!